Sarah Cannon Research Institute | Strategic Alliance Partners

Explore how pharmacists can support patients with pancreatic cancer taking atebimetinib as Immuneering leaders and oncologists discuss tolerability, education, and survival-focused phase 3 trial goals.

Experts discuss how atebimetinib and adjusted chemotherapy schedules enhance tolerability and treatment duration for patients with pancreatic cancer.

Experts discuss groundbreaking data on pancreatic cancer treatment, revealing a 64% survival rate and its potential to transform patient care and outcomes.

Atebimetinib shows promise in enhancing pancreatic cancer treatment, achieving a 64% survival rate and improving patient quality of life.

Explore the HER2CLIMB-05 study's findings on tucatinib's impact on breast cancer progression-free survival, enhancing treatment options for pharmacists.

Vepdegestrant was the first PROTAC to be evaluated in a phase 3 clinical trial.

A study reveals a 14-gene assay guides chemotherapy decisions effectively in patients with early-stage non-small cell lung cancer (NSCLC).

Compared with fulvestrant, vepdegestrant significantly extended progression-free survival and improved response rates.